MDxHealth
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and personalized treatment of patients.
Top Stages
2 past transactions
Exact Sciences - Oncotype DX GPS Prostate Cancer Business
Acquisition in 2022
Exact Sciences’ Precision Oncology portfolio of genomic tests provide physicians and patients with personalized insights about the patient’s tumor, allowing them to make treatment decisions with a greater degree of confidence.
NovioGendix
Acquisition in 2015
NovioGendix, established in 2008, is a Dutch molecular diagnostics company specializing in non-invasive liquid biopsy tests for prostate cancer. Based in Nijmegen, it offers services such as the PCA3 Test and PROGENSA PCA3 urine test for prostate cancer detection and management. The company also develops molecular diagnostic assays for various urologic cancers, collaborating with Radboud University Medical Center. Its shareholders include BioGeneration Ventures and Participatiemaatschappij Oost Nederland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.